Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy

References

• Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47–91.
   PubMed Web of Science ®Google Scholar
• Larubbia JR. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol 2013;19:1349–53.
   PubMedGoogle Scholar
• Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851–6.
   PubMed Web of Science ®Google Scholar
• Lu Y, Jacobson DL, Ashworth LA, Grand RJAL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009;104:444–53.
   PubMed Web of Science ®Google Scholar
• Andrisani G, Frasca D, Romero M, Armuzzi A, Felice C, Marzo M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis 2013;7:301–7.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5–36.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern FJr. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
   PubMed Web of Science ®Google Scholar
• Ellebedy AH, Webby RJ. Influneza vaccines. Vaccine 2009;27:65–8.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune mediated inflammatory diseases. Rheumatology 2010;49:1815–27.
   PubMed Web of Science ®Google Scholar
• Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834–40.
   PubMed Web of Science ®Google Scholar
• Shale M, Czub M, Kaplan GG, Panaccione R, Ghosh S. Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Ther Adv Gastroenterol 2010;3:173–7.
   PubMedGoogle Scholar
• deBruyn JC, Hilsden R, Fonseca K, Russell ML, Kaplan GG, Vanderkooi O, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:25–33.
   PubMed Web of Science ®Google Scholar
• Gelinck LBS, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor a treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713–16.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, et al. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I–II randomized trial. Vaccine 2010;28:6221–7.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Walker WT, Finn A, Heath PT, Collinson AC, Pollard AJ, et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine 2011;29:7913–19.
   PubMed Web of Science ®Google Scholar
• Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009;60:2438–47.
   PubMedGoogle Scholar
• Long CB, Ramos I, Rastogi D, Manwani D, Janow G, Del Rio M, et al. Humoral and cell-mediated immune responses to monovalent 2009 Influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. J Pediatr 2012;160:74–81.
   PubMed Web of Science ®Google Scholar
• Ershler WB, Coe CL, Gravenstein S, Schultz KT, Klopp RG. IV. The correlation of in vitro and in vivo antibody response to influenza vaccine in rhesus monkeys. Clin Exp Immunol 1988;73:355–9.
   PubMedGoogle Scholar
• Ershler WB, Moore AL, Socinski MA. Specific antibody synthesis in vitro. III. Correlation of in vivo and in vitro antibody response to influenza immunization in young and old subjects. J Clin Lab Immunol 1985;16:63–7.
   PubMedGoogle Scholar